NASDAQ:GBIO

Delisted

Generation Bio Stock News

Healthcare > Biotechnology

Buy GBIO

*Your capital is at risk

$5.34

+0 (+0%)

At Close: May 05, 2026

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

07:30pm, Sunday, 15'th Mar 2026

INCHEON, Korea--(BUSINESS WIRE)-- #Biosimilar--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a res

Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages

04:18am, Sunday, 01'st Mar 2026

Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has earned an average rating of "Hold" from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has r

Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25

01:44am, Friday, 19'th Dec 2025

Generation Bio Co. (NASDAQ: GBIO - Get Free Report) has been assigned an average rating of "Hold" from the six research firms that are covering the firm, MarketBeat.com reports. One analyst has rated

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

08:21pm, Monday, 15'th Dec 2025

MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced t

GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

07:38pm, Monday, 15'th Dec 2025

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and o

XOMA Royalty Enters into Agreement to Acquire Generation Bio

05:00pm, Monday, 15'th Dec 2025

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -

Generation Bio Announces Third Quarter 2025 Financial Results

04:05pm, Wednesday, 05'th Nov 2025

CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results.

Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)

03:58am, Thursday, 30'th Oct 2025

Generation Bio (NASDAQ: GBIO - Get Free Report) and Nuvation Bio (NYSE: NUVB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two busine

Generation Bio Announces CEO Transition

04:05pm, Wednesday, 22'nd Oct 2025

• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

06:31pm, Tuesday, 12'th Aug 2025

Generation Bio Co. (GBIO) came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago.

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

04:05pm, Tuesday, 12'th Aug 2025

• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdow

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by